Close Menu

Daniel Sikkema

Jul 19, 2017

Quanterix has appointed Daniel Sikkema as vice president of acclerator services for the company's new Simoa Accelerator Lab, a dedicated environment for biomarker research, custom assay development, and clinical sample testing. Sikkema will work to expand the reach of Quanterix's Accelerator Lab services in neurology, oncology, immuno-oncology, infectious disease, inflammatory diseases, and other therapeutic areas. He has previously worked at Frontage Lab, Bristol-Myers Squibb, Wyeth, Merck, Sanofi Pasteur, and GlaxoSmithKline.

More Like This

Jul 12, 2019

Alexander Mackinnon

Alexander “Craig” Mackinnon has become the inaugural director of the Division of Genomics, Diagnostics, and Bioinformatics in the Department of Pathology at the University of Alabama at Birmingham School of Medicine. He will lead ongoing efforts to establish a Precision Diagnostic Laboratory at UAB. 

Mackinnon is a board-certified anatomical and molecular genetic pathologist. Previously, he was associate professor in the Department of Pathology at the Medical College of Wisconsin, where he directed the Clinical and Translational Research Laboratory, which developed multiple sequencing-based panels targeting variants in both DNA and RNA. 

Jul 10, 2019

Keng Hsu

Keng Hsu has stepped down from the board of Yourgene to improve the balance of executive and non-executive directors and to allow him to focus on business development in Asia. Yourgene plans to add non-executive directors to its board in the near future.

Jul 09, 2019

Christopher Thibodeau

OncoCell MDx has appointed Christopher Thibodeau as chief operating officer. Prior to OncoCell MDx, Thibodeau served as COO at MDxHealth. Before MDxHealth, he held various positions at Agendia, Numira Biosciences, LabCorp's US LABS, and Roche Diagnostics' Ventana Medical Systems 

Jul 03, 2019

Steven Averbuch

Steven Averbuch has joined Caris Life Sciences' scientific advisory board. Averbuch recently retired from the role of vice president and head of precision medicine in the translational medicine division of R&D at Bristol-Myers Squibb. During his tenure, Averbuch spearheaded the Pharmacodiagnostics Center of Excellence, which led to the application of BMS' precision medicine strategy across all therapeutic areas. Prior to this, Averbuch oversaw corporate-wide strategic initiatives for translational and targeted medicine at BMS. He also served as head of early global clinical research at the company. Averbuch also previously held leadership roles with Merck Research Laboratories and AstraZeneca, and held academic appointments at Mount Sinai School of Medicine and the US Public Health Service School of Medicine.

Jul 03, 2019

Jonathan Genzen

ARUP Laboratories appointed Jonathan Genzen as its chief operating officer effective July 1. Genzen has held a number of positions since starting at ARUP in January 2013. He served as its chemistry section chief and medical director for its automated core laboratory, laboratory automation, and Farmington clinical laboratory, among other responsibilities. Prior to joining ARUP, Genzen was a faculty member in the Department of Pathology and Laboratory Medicine at Weill Cornell Medical College.

Jul 02, 2019

Troy Cox

Troy Cox has joined Sophia Genetics' board of directors. Cox previously was CEO of Foundation Medicine, which was acquired by Roche last year. Prior to that he was senior vice president and an officer at Genentech. He has also held executive and senior positions with UCB BioPharmaceuticals, Sanofi-Aventis, and Schering-Plough.

Jul 02, 2019

Grace Colón

CareDx has appointed Grace Colón to its board of directors.  Colón currently served as president, CEO, and director of InCarda Therapeutics. She is also executive chairman of ProterixBIo and is on the board of Cocoon Biotech. Colón previously served on the boards of Paradigm Diagnostics and PerceptiMed. Colón has also served as a partner at New Science Ventures and held various leadership roles at Intrexon, Gilead Sciences, and Affymetrix. She will succeed Amy Abernethy on CareDx's board. 

Jul 01, 2019

David Rubin, Timothy Harris

David Rubin and Timothy Harris informed OpGen that they would be leaving the company's board, effective June 30. OpGen disclosed the resignations in a document filed with US Securities and Exchange Commission on July 1. Both had been on OpGen's board since 2015. The company said there had been no disagreement with Rubin or Harris leading to their resignations. 

Jul 01, 2019

Keith Kennedy

Veracyte has appointed Keith Kennedy as chief operating officer. Prior to joining Veracyte, Kennedy served as executive leadership positions at MCG Capital, Arlington Capital Partners, and GE Capital over the past 20 years.

Jun 28, 2019

Eugene Durenard, Ted Murphy

Co-Diagnostics have appointed Eugene Durenard and Ted Murphy to its board of directors, and will serve on the board's compensation and corporate governance/nomination committees and audit committees as independent directors. The two new members will be replacing Frank Kiesnar, who resigned as director of the firm, and Edward Borkowski, who retired as a director of the firm.

Durenard has been founder and CEO of Hyperbolic Holdings since 2018, co-founder and chief innovation officer of Healthcare Impact Holdings since May 2018, co-founder and trustee of Healthcare Impact Foundation since 2017, co-founder of Global Better Health since December 2018, as well as advisor and managing director of the Stetson Family Office since September 2016.

Murphy serves on the board of directors of three Canadian publicly reporting companies, as well as a senior partner in a private investment firm since 1999.

Jun 27, 2019

Thomas West

Hologic announced that Thomas West, its diagnostics division president, resigned effective July 1. In a filing with the US Securities and Exchange Commission, the firm said he is leaving Hologic to assume the role of CEO at another publicly traded company.

Jun 26, 2019

Margot Schoenborn

OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO. Schoenborn joined the firm as senior VP, general counsel and corporate secretary in 2015 and was later appointed chief administrative officer. Prior to OmniSeq, Schoenborn served as deputy general counsel at the Roswell Park Comprehensive Cancer Center. Before that, she served as a special assistant attorney general for New York and as a assistant US attorney for the Eastern District of New York. 

Jun 26, 2019

Stefano Giolito

RevoluGen has appointed Stefano Giolito as chief marketing officer. With more than 20 years of marketing and research and development experience, Giolito previously served as marketing global VP at Unilever. 

Jun 26, 2019

Katie Breitenbach and Viktor Novy

CureMatch said today that it has hired Katie Breitenbach as chief financial officer and Viktor Novy as chief technical officer. Breitenbach brings experience with venture-backed startups and preparation for initial public offerings the software and cloud-services industries. Novy is a former IT director at Human Longevity. CureMatch is a San Diego-based startup that provides artificial intelligence-driven oncology treatment analysis services, including clinical decision support.

Jun 25, 2019

Rupert Vessey

Bio-Techne appointed Rupert Vessey as an independent director to its board of directors, bringing the total number of board members to nine.

He is the president of global research and early development at Celgene. Before joining Celgene, Vessey held various R&D senior management positions at Merck. Previously, he worked in drug discovery, experimental medicine, and early clinical development at GlaxoSmithKline.

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.